1-866-598-7166

Stereotactic Body Radiotherapy (SBRT) for Radiation Resistant Bone Tumours

Trial ID: NCT04177056
Kidney Cancer Type: Any


Background:

Up to 30% of patients with advanced kidney cancer may develop bone tumours which have spread from their primary kidney cancer. These bone tumours can be painful and significantly reduce a patient’s quality of life.

In other cancers, radiation therapy is a mainstay treatment for bone tumours. Unfortunately, kidney cancer is highly resistant to traditional radiation therapy.

Stereotactic body radiotherapy (SBRT) is a newer form of focussed treatment that gives higher doses of radiation without causing damage to surrounding tissues. The higher levels of radiation provided by SBRT may be able to combat this resistance to radiotherapy.


The Trial:

The purpose of this trial is to explore the safety and effectiveness of giving SBRT to kidney cancer patients experiencing pain from their uncontrolled bone tumours.

Patients enrolling on this trial will receive 5 SBRT treatments, called “fractions”, spread over a number of days.

Patients will be monitored for decreases in pain response for 3-6 months after treatment.


Basic Eligibility:

  • Diagnosis of advanced kidney cancer
  • Up to 5 bone tumours may be treated with SBRT

Additional eligibility criteria will apply. Please speak to your doctor.

 

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreJuravinski Cancer Centre Principal InvestigatorDr. Anand Swaminath LocationHamilton, Ontario Trial StatusNot yet recruiting
Do NOT follow this link or you will be banned from the site!